Thursday, October 10, 2013




Oct. 6, 2013 — Glutamergic agents may one day be used as a novel treatment for mood and anxiety disorders, new research presented at the 26th ECNP Congress suggests. 
(Science Daily, Mind and Brain News)

Professor Sanacora presented a series of preclinical and clinical studies indicating that a novel class of drugs that target components of the glutamatergic neurotransmitter system may produce rapid and robust antidepressant effects.
"There is a rapidly expanding literature suggesting the glutamatergic neurotransmitter system is altered in the brains of individuals suffering with mood disorders," explains Professor Sanacora.
There is also increasing evidence suggesting stress may disrupt normal glutamtergic function in the brain and may be a mechanism contributing to the pathogenesis of several stress-related neuropsychiatric disorders," he adds.
Their research, due to be published in the journal Molecular Psychiatry, adds to this body of evidence.
"First and foremost, our findings suggest the glutamatergic system is a truly viable target for antidepressant drug development," concludes Professor Sanacora